RATIONALE: ‘Party Pills’ containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been used in a recreational context since the 1990s and, prior to April 2008, were legally available in New Zealand. Taken together, they have been reported to produce a ‘high’ similar to that produced by 3,4-methylenedioxymethamphetamine (MDMA). OBJECTIVES: There has been little research on the subjective effects of piperazines in humans. The purpose of this study is to further investigate the subjective and physiological responses following an oral dose of BZP combined with TFMPP in males. METHODS: In a randomised, double-blind, placebo-controlled study the subjective and physiological effects of BZP/TFMPP were investigated in 36 healthy, non-smoking males (mean age 22 ± 4 years). Participants were tested before and approximately 120 min after administration of a single dose of placebo (n = 16) or 100/30 mg BZP/TFMPP (n = 20). Participants were required to comment on the subjective effects using three rating scales—the Addiction Research Centre Inventory (ARCI), the Visual Analogue Scale (VAS) and the Profile of Mood States (POMS). Participants' blood pressure, heart rate and body temperature were also measured. RESULTS: Statistical analysis using repeated-measures analysis of variance (ANOVA) and planned comparisons revealed that BZP/TFMPP significantly increases blood pressure and heart rate (p < 0.05). Likewise, the subjective rating scales revealed that BZP/TFMPP has significant dexamphetamine-like effects, increases dysphoria and feelings of self-confidence (p < 0.05). CONCLUSION: These physiological and subjective data reflect clear similarities between the effects of BZP/TFMPP and commonly known stimulants such as dexamphetamine and MDMA.
RCT Entities:
RATIONALE: ‘Party Pills’ containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been used in a recreational context since the 1990s and, prior to April 2008, were legally available in New Zealand. Taken together, they have been reported to produce a ‘high’ similar to that produced by 3,4-methylenedioxymethamphetamine (MDMA). OBJECTIVES: There has been little research on the subjective effects of piperazines in humans. The purpose of this study is to further investigate the subjective and physiological responses following an oral dose of BZP combined with TFMPP in males. METHODS: In a randomised, double-blind, placebo-controlled study the subjective and physiological effects of BZP/TFMPP were investigated in 36 healthy, non-smoking males (mean age 22 ± 4 years). Participants were tested before and approximately 120 min after administration of a single dose of placebo (n = 16) or 100/30 mg BZP/TFMPP (n = 20). Participants were required to comment on the subjective effects using three rating scales—the Addiction Research Centre Inventory (ARCI), the Visual Analogue Scale (VAS) and the Profile of Mood States (POMS). Participants' blood pressure, heart rate and body temperature were also measured. RESULTS: Statistical analysis using repeated-measures analysis of variance (ANOVA) and planned comparisons revealed that BZP/TFMPP significantly increases blood pressure and heart rate (p < 0.05). Likewise, the subjective rating scales revealed that BZP/TFMPP has significant dexamphetamine-like effects, increases dysphoria and feelings of self-confidence (p < 0.05). CONCLUSION: These physiological and subjective data reflect clear similarities between the effects of BZP/TFMPP and commonly known stimulants such as dexamphetamine and MDMA.
Authors: Reem K Jan; Joanne C Lin; Heeseung Lee; Janie L Sheridan; Rob R Kydd; Ian J Kirk; Bruce R Russell Journal: Psychopharmacology (Berl) Date: 2010-06-16 Impact factor: 4.530
Authors: I Thompson; G Williams; B Caldwell; S Aldington; S Dickson; N Lucas; J McDowall; M Weatherall; G Robinson; R Beasley Journal: J Psychopharmacol Date: 2009-03-27 Impact factor: 4.153
Authors: Louise E Curley; Rob R Kydd; Michelle C Robertson; Avinesh Pillai; Nicolas McNair; HeeSeung Lee; Ian J Kirk; Bruce R Russell Journal: Psychopharmacology (Berl) Date: 2015-04-19 Impact factor: 4.530
Authors: Tibor M Brunt; Maarten W Koeter; Raymond J M Niesink; Wim van den Brink Journal: Psychopharmacology (Berl) Date: 2011-10-13 Impact factor: 4.530
Authors: HeeSeung Lee; Grace Y Wang; Louise E Curley; Rob R Kydd; Ian J Kirk; Bruce R Russell Journal: Psychopharmacology (Berl) Date: 2016-06-11 Impact factor: 4.530